Dual-action architecture
Microbiome Rebalancing Peptide + Fermented Capsule
Crohn's disease symptom support + gut barrier restoration
Support microbial resilience against environmental contaminants
Peptide
Candidate host-defense / LL-37 analog or engineered AMP
host-defense / engineered AMP
- — barrier reinforcement
- — selective antimicrobial activity
- — anti-inflammatory signaling
- — possible antifibrotic effect
Requires protection from upper-GI degradation (alginate, targeted release, or bacteriocin-transport inspired systems).
preclinical
Fermented matrix
Multi-strain fermented / next-gen probiotic matrix
live + postbiotic hybrid preferred
- — Faecalibacterium prausnitzii lineage (or equivalent butyrate producer)
- — Selected Lactobacillus / Bifidobacterium strains
- — Optional Akkermansia or other mucus-associated taxa
- — Fermented food derived postbiotics / prebiotic fraction
mixed (stronger in UC than CD; emerging for contaminants)
Formulation
- Dual-compartment or co-encapsulated design preferred
- Colon-targeted or ileal-targeted release desirable
- Stability of both peptide and live components is critical
Exploratory R&D → potential LBP / peptide drug or carefully limited supplement